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Abstract : The effect of halothane anesthesia in different doses and a period of two weeks on glucose-6-phosphate dehydrogenase
(G6PDH) activity of mouse liver were investigated. The mean and SD of G6PDH for liver of normal mice were 0.036±0.017 U/mg
protein and 1.756±0.814 U/g liver, respectively. Although there was histopathological damage in the liver, liver weights in treated
mice increased significantly compared to control animals. Increasing the dosage of halothane inhalation induced liver G6PDH enzyme
activity (U/g liver) by 84%, 42% and 4%, showing an inverse relation with the dose of halothane (0.25, 0.50, 1.00 cc twice daily
for two weeks). Although the Michaelis constant (Km) of the partially purified enzyme for glucose-6-phosphate (G6P) and
nicotinamide adenine dinucleotide phosphate (NADP) were similar, the utilization of analogs as 2-deoxyglucose-6-phosphate (2dG6P), galactose-6-phosphate (Gal-6P) and nicotinamide adenine dinucleotide (NAD) were different. The induced enzyme was more
heat stable than the control.
Key Words : Halothane, G6PDH, mouse liver, induction, kinetic properties

Halotan ile Olußturulan KaraciÛer Glukoz-6-Fosfat Dehidrogenaz ÜndŸksiyonunun
DeÛerlendirilmesinde Bir Fare Modeli
…zet : Bu •alÝßmada, iki haftalÝk zaman periyodunda uygulanan farklÝ dozlardaki halotan anestezisinin fare karaciÛer glukoz-6-fosfat
dehidrogenaz (G6PDH) aktivitesine etkisi araßtÝrÝlmÝßtÝr. Normal fare karaciÛerinde G6PDH aktivitesinin ortalamasÝ (±SD)
0,036±0,017 †/mg protein ve 1,756±0,814 †/g karaciÛer olarak bulunmußtur. Anestezi uygulanan farelerin karaciÛerlerinde
histopatolojik hasar olußtuÛu ve karaciÛer aÛÝrlÝklarÝnda da anlamlÝ artÝß olduÛu saptanmÝßtÝr. Artan dozlarda (2 haftada gŸnde 2 kez
0,25, 0,50, 1,00 cc) halotan inhalasyonunun %84, %42 ve %4 (†/g karaciÛer) oranlarÝnda karaciÛer G6PDH aktivitesini azaltmasÝ,
halotan dozu ile enzim aktivitesi arasÝnda ters ilißki olduÛunu gšstermektedir. Kontrol ve anestezi uygulanan gruplarda, kÝsmi
saflaßtÝrÝlmÝß enzimin glukoz-6-fosfat ve nikotinamid adenin dinŸkleotid fosfat michaelis sabiteleri (Km) benzemekte iken, 2deoksiglukoz-6-fosfat, galaktoz-6-fosfat ve nikotinamid adenin dinŸkleotid gibi substrat analoglarÝnÝn kullanÝmÝ yšnŸnden farklÝlÝk
gšsterdiÛi saptanmÝßtÝr. ÜndŸklenen enzimin ÝsÝ stabilitesinin kontrolden daha fazla olduÛu saptanmÝßtÝr.
Anahtar SšzcŸkler : Halotan, G6PDH, fare karaciÛeri, indŸksiyon, kinetik šzellikler

Introduction
Glucose-6-phosphate dehydrogenase (G6PDH, EC
1.1.1.49) is the first and key regulatory enzyme of the
pentose phosphate pathway. The main physiological role
of G6PDH is to provide reduced nicotinamide adenine
dinucleotide phosphate (NADPH), a compound necessary
for a number of biosynthetic reactions, including fatty
acid synthesis, and the reducing equivalents maintain the
redox state of the cell. It is a ÔhousekeepingÕ enzyme
constitutively expressed in all cell types and in all

organisms thus far analyzed. However, there are tissues
such as liver, adipose, lung and proliferating cells where
G6PDH activity responds to external stimuli such as
hormones, growth factors, nutrients and oxidative stress,
thus showing adaptive capacity (1-4).
Halothane has been widely used as an inhalational
anesthetic since 1957 and is metabolized in the liver as
a lipophilic xenobiotic to hepatotoxic intermediates by
monooxygenases using cytochrome P4502E1 system
(CYP2E1). The free radicals generated during the
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metabolism of halothane are quenched by the antioxidant
system present in the living cell as superoxide dismutase
(SOD), catalase (CAT), glutathione reductase (GSH-R),
glutathione peroxidase (GSH-P), reduced glutathione
(GSH) and eventually the final electron acceptor NADPH
generated by G6PDH (5-8).
Since human and mouse G6PDH enzyme show
homology (9-11), a mouse model could be used for
evaluating the effect of halothane anesthesia on the
induction of G6PDH enzyme.

Materials and Methods
Chemicals: Nicotinamide adenine dinucleotide
phosphate (NADP), glucose-6-phosphate (G6P), 2deoxyglucose-6-phosphate (2d-G6P), galactose-6phosphate (Gal-6P), nicotinamide adenin dinucleotide
(NAD), deamino-nicotinamide dinucleotid phosphate
(dNADP), bovine serum albumin (BSA), (3-[4,5Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT)) and phenazine methosulfate (PMS) were obtained
from the Sigma Chemical Co. DE-52 was from Whatman
(Maidstone, England). All the other chemicals were
analytical grade products of Merck (Darmstadt,
Germany).
Animals: Male, non-inbred Mus musculus albino
mice, 6-10 weeks old, weighing 31±2 g were obtained
from the Medical Sciences Experimental Research Center
of the University of ‚ukurova. They were fed a standard
laboratory diet and tap water. Illumination was 12 hour
light/dark cycle and room temperature was 22-24¼C.
The control group consisted of fifteen apparently normal
mice and fifteen were anesthetized with halothane. The
anesthetized group was subdivided into three subgroups
(a, b and c) which were given halothane 0.25 cc, 0.50 cc
and 1.00 cc respectively through inhalation over 30
minutes twice daily at 8.00 AM and 4.00 PM for a period
of two weeks. The mice were weighed before sacrifice.
The livers were quickly removed, weighed and
homogenized with three volumes of ice-cold 0.25 M
sucrose. The activity of G6PDH enzyme was measured in
105,000 x g supernatant.
Enzyme Activity: Activity was determined at 37¼C in
the homogenate according to the procedure of Beutler
(12). The protein concentrations were measured using
BSA as the standard (13). The specific activity of the
enzyme was calculated for homogenate as U/mg protein
and U/g liver.
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Biochemical Parameters: Kinetic studies followed
the procedure of the WHO scientific group. G6PDH from
mouse liver was partially purified by ion exchange with
DE-52 as the ligand. The steady-state kinetic parameters
were obtained spectrophotometrically using a Shimadzu
U.V. 260 instrument. Michaelis constants (Km) for G6P
and NADP were determined in partially purified enzyme
at 37¡C. G6P concentrations ranged from 10 to 1000
µM and NADP concentrations from 0.8 to 30 µM in the
Km studies. The utilization rates of 2d-G6P, Gal-6P,
dNADP, and NAD were measured. The heat stability of
G6PDH enzyme was determined after 10 and 20 minutes
incubation at 46¼C (14). Polyacrylamide gel
electrophoresis (PAGE) was performed using 0.08 M
Tris-HCI buffer, pH 8.0, at room temperature. Before
electrophoresis, samples were dialyzed 2 hours at +4¼C
against running buffer. The active band was stained by
the staining solution containing 0.3 mM PMS, 2.8 mM
MTT, 2mM NADP and 6 mM G6P in 10 ml. The gel was
destained in 10% acetic acid at room temperature (15).
The protein concentration of the liver was determined in
a Shimadzu UV 120-02 spectrophotometer following the
procedure of Lowry using BSA as a standard.
Histopathology: The liver tissues were fixed in 10%
formaldehyde and processed routinely. They were
embedded in paraffin. Five µm sections were obtained,
stained with Harris hematoxylene-eosin and examined
under a light microscope (16).
Statistics: The SPSSX program was used for the
Wilcoxon-Mann-Whitney rank sum test (U test). Results
were expressed as the means ± standard deviation (SD).

Results
Whereas anesthesia had no significant effect on the
total body weight (p>0.05) of the mice, it did increase
the weight of the livers as shown in Table 1, although the
increase was barely significant (p<0.05). Table 2 shows
the effects of anesthesia on G6PDH activity in the liver.
Figure 1 shows the results of the thermal inactivation
studies in the control group and in the anesthetized
group. The thermal inactivation properties of the control
group and the anesthetized group were also significantly
different. The relative utilization of NAD, 2d-G6P and
Gal-6P was significantly different as shown in Table 3.
PAGE of both the control and the anesthetized group
gave a single homogenous band and no differences in
electrophoretic mobility were noted.
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Table 1.

Liver weights of control and anesthetized mice.

Table 2.

G6PDH activities of liver of control and anesthetized mice.

Liver weights (g)

G6PDH activities

Groups

Groups

Control
(a)
(b)
(c)

n

X±SD

max

min

U-test

15
5
5
5

1.37±0.01
2.79±0.66
2.13±0.54
1.54±0.26

1.75
3.93
2.98
1.99

1.02
2.23
1.53
1.31

p<0.05
p<0.05
p>0.05

Control
(a)
(b)
(c)

n

U/mg protein

U-test

U/g liver

U-test

15
5
5
5

0.036±0.017
0.052±0.037
0.039±0.011
0.028±0.008

p<0.05
p>0.05
p<0.05

1.756±0.814
3.239±0.756
2.498±1.193
1.840±0.832

p<0.05
p<0.05
p>0.05

p<0.05 was considered significant

p<0.05 was considered significant

In groups a, b and c 0.25 cc, 0.50 cc and 1.00 cc of halothane,
respectively, were given twice daily for two weeks.

In anesthetized groups a, b and c 0.25 cc, 0.50 cc and 1.00 cc
halothane, respectively, were given twice daily for two weeks.

Anesthetized group

Figure 1.

control group

G6PDH ACTIVITY
(% of maximal activity)

120
100
80

Thermal inactivation of mouse liver
G6PDH enyzme of control and
anesthetized mice.
The partially purified enzyme was
incubated at 46¼C. The G6PDH
activity was measured at 0, 10, 20
min intervals.

60
40
20
0
0 min.

10 min.

20 min.

TIME

Table 3.

Biochemical properties of partially purified liver G6PDH of control and anesthetized (c) group.
Km

Utilization (%)

Groups

Control
Anesthetized

G6P
(µ M)

NADP
(µ M)

2d-G6P

Gal-6P

dNADP

NAD

66.1±23.7
63.4±11.4

1.8± 0.2
2.1± 0.9

4±8
*14±5.9

0
* 3.0±3.7

48.0±9.8
5.2± 3.3

57±34.7
*73 ±11.9

Heat stability (%
activity remaining
after 20 min.
Incubation 46¼C)
69.0±10.1
*98.7±6.3

* Significantly different (p<0.05) from the value obtained with control
In group c, 1.00 cc of halothane was given twice daily for two weeks.

Microscopic examinations of the liver tissues showed
eosinophil leukocyte and mononuclear inflammatory cell
infiltration on portal tracts. Cloudy degenerations,
congestions, micro- and macrovesicular fatty
degeneration, spotty necrosis and centrilobuler necrosis
of the parenchymal cells were observed (Figure 2).

Discussion
Whereas the mechanism of halothane (2-bromo-2chloro-1-1 trifluoroethane) anesthesia is still disputed, it
is well established that the xenobiotic is metabolized in
the liver through the P4502E1 system (CYP2E1) to
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Figure 2.

hepatoxic intermediates. The highly reactive free radicals
generated during the course of the reaction are detoxified
by GSH and/or by the final electron acceptor NADPH
produced by the G6PDH enzyme (5-8, 17). In this study,
also, we observed the toxic effects of long-term exposure
to halothane anesthesia on the liver. As shown in Figure
2, the livers of mice suffered histopathological damage,
changes in liver morphology were prominent and
degeneration and necrosis of parenchymal cells were
common. However, even after two weeks of anesthesia
the livers increased in weight although no increase in
body weight was observed. The increase in weight was
significant and greatest in the low-dose anesthetic thus
showing an inverse relation to the dosage of halothane.
Even with the highest dose (1.00 cc twice daily for 2
weeks) the weight of the livers was greater compared to
the control group. Similar observations were noted with
the effect of ozone in the lung (18). Our most significant
observation was the response of G6PDH enzyme to the
xenobiotic halothane. The liver G6PDH enzyme also
showed an inverse relation to the dose of halothane; the
increase in enzyme activity was greatest with the low
dose and decreased as the dose was increased. As with
the liver weights, even with the highest exposure dose of
halothane, the enzyme activity was higher than that of
the control group. Similar inductions of mouse liver
G6PDH were noted with exposure to phenylhydrazine
and aflatoxin over a period of time (19,20). However,
although the inductions of the enzyme were observed, no
biochemical characterization of the enzymes was
performed. In our experiments we partially purified and
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The tissue taken from the anesthetized group
of
Mus musculus albino mouse
(Hematoxylene Eosin x375).
Liver tissue showing congestion, cloudy
swelling, micro and macro vesicular fatty
degeneration.

characterized the enzymes obtained from the livers of
mice exposed to the highest halothane dose. The
Michaelis constant (Km) of the substrate G6P and
cofactor NADP were similar in the control and the
anesthetized mouse liver. However, the utilizations of the
analogs as 2d-G6P, Gal-6P and NAD were significantly
different. Also, the heat stability of the induced enzyme
was significantly changed, the latter being more stable.
These data suggest that a variant of G6PDH enzyme is
induced. Repression of G6PDH enzyme was first obtained
by Pretsch et al. who first showed an X-linked deficient
G6PDH enzyme in the offspring of mice by inbreeding
normal mice with 1-ethyl-1-nitrosurea-treated male mice.
The authors demonstrated that the repressed G6PDH
enzyme was a variant of normal liver G6PDH by
biochemical characterization. Similar variant results were
obtained by Neifer et al., who characterized the variant
obtained from 1-ethyl-1-nitrosourea-treated mice
(21,22). However, no one has yet analyzed for the
mutation in the gene. As is well known some variants
have the same mutation although they differ in kinetic
properties and vice versa (2,23,24). All these data
support the model for the positive and negative effects
(manipulations) suggested by Kletzien for the control of
the G6PDH gene expression (4).

Conclusions
1. G6PDH enzyme was successfully used as a
biomarker for the development of the hepatocellular
defense against halothane.
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2. G6PDH enzyme is induced in the liver although the
livers suffered injury.
3. The induced enzyme had more heat stability and
could use analogs as well.
4. Given the homology between human and mouse
G6PDH, and since the mouse model is easy to manipulate,
the G6PDH enzyme can successfully be used as a

biomarker for the effect of different xenobiotics, drugs
or carcinogens on the liver.
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